Jiangsu Hengrui Medicine (600276) Fundamentals 2026 — P/E 44.3x, Revenue Analysis | SniperIQ
Jiangsu Hengrui Medicine (600276) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥353.3B, trading at ¥55.39 on the SHH. This SniperIQ fundamentals page covers Jiangsu Hengrui Medicine's valuation (P/E 44.3x, P/B 5.7x), profitability (net margin 24.9%), revenue (¥31.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jiangsu Hengrui Medicine's market cap?
Jiangsu Hengrui Medicine (600276) has a market capitalization of approximately ¥353.3B, trading at ¥55.39 on the SHH. Market cap moves with the live share price.
What is Jiangsu Hengrui Medicine's P/E ratio?
Jiangsu Hengrui Medicine's trailing twelve-month P/E ratio is 44.3x, with a price-to-book (P/B) of 5.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jiangsu Hengrui Medicine?
Jiangsu Hengrui Medicine runs a net profit margin of 24.9%, a gross margin of 86.2%, and an operating margin of 27.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jiangsu Hengrui Medicine generate?
Jiangsu Hengrui Medicine reported revenue of ¥31.4B for fiscal year 2025, with net income of ¥7.7B and earnings per share (EPS) of 1.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jiangsu Hengrui Medicine pay a dividend?
Jiangsu Hengrui Medicine offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jiangsu Hengrui Medicine financially healthy?
Jiangsu Hengrui Medicine carries a debt-to-equity ratio of 0.00x and a current ratio of 9.23x, with a market beta of 0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jiangsu Hengrui Medicine a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jiangsu Hengrui Medicine (600276) the key facts are: market cap ¥353.3B, P/E 44.3x, revenue ¥31.4B, 52-week range 45.26-74.04. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jiangsu Hengrui Medicine's full fundamentals live
Get Jiangsu Hengrui Medicine's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.